Yeah, so this is the first time we test a TDP43 tracer in humans. This is very, very exciting because there is an important need for TDP43 biomarkers, in particular for TDP43 imaging biomarkers, because it’s important to stage the degree of TDP43 pathology to understand whether this is actually causing symptoms or problems, as well as in patients. So, yeah, having a PET tracer that, you know, in principle is able to visualize these TDP43 aggregates is extremely, extremely important...
Yeah, so this is the first time we test a TDP43 tracer in humans. This is very, very exciting because there is an important need for TDP43 biomarkers, in particular for TDP43 imaging biomarkers, because it’s important to stage the degree of TDP43 pathology to understand whether this is actually causing symptoms or problems, as well as in patients. So, yeah, having a PET tracer that, you know, in principle is able to visualize these TDP43 aggregates is extremely, extremely important. This preliminary data, the results seem to be promising with the elevations in patients with mutations that are associated with the presence of TDP43. All you see elevations in different brain regions that in principle are consistent with what we would expect in these conditions. This is very preliminary data, promising data, but we need to further study this in other TDP43 conditions to understand the full potential and the limitations of this new tracer. So in summary, it’s promising data, but we need further evaluation to understand the potential of this space.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
